Please Wait
Applying Filters...
menu
    • menu
    Medical Breakthroughs in 2024: Alzheimer’s, schizophrenia, COPD, MASH see pathbreaking treatments

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Oct 2024: Lundbeck acquires Longboard for US$ 2.6 bn; molecular glue degrader tech witnesses dealmaking

    Stock Recap
    #PipelineProspector

    Menu

    AVYCAZ

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 374Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Registrant Name MF Registration No. Classification Initial Date of Reg. Latest Date of Reg. Registrant's Address
    26/09/2024 ACS DOBFAR SPA
    Italy
    		 ACS DOBFAR S. p. A. 305MF10039 Ceftazidime Hydrate 2023-03-23 2024-05-08 Viale Addetta, 4/12, 20067 Tribiano (Milan) Italy
    26/09/2024 CJ CheilJedang Center
    South Korea
    		 CJ CheilJedang Corporation 219MF10143 Ceftazidime hydrate 2007-04-27 2009-07-09 CJ CheilJedang Building 292, Ssangnim-dong, Jung-gu, Seoul, 100-400, Korea